Ann: Orocobre and Galaxy Merger - Announcement, page-320

First 320 Last

Share
Profile

Follow
butcherboy

20,020 Posts.

870

20/04/21

10:29

Post #: 52585859
Share

Originally posted by Thesi: ↑

Wonder what happens to Livent now? Will the new entity continue to sell to Livent? Orocobre is who Livent has been receiving their 3rd party supply from which has allowed them to put off expanding at Salar del Hombre Muerto.

I am sure Livent along with a number of other parties will be considering the ramifications of this merger, and in Livent's case will probably encourage them to proceed with their expansion at Fenix much sooner.

If Tesla had hoped to receive supply from James Bay, maybe that will still happen, or maybe Toyota might not want to provide that to them. This deal very much placed the ball in Toyota's court. Whilst I have heard commentary that the merged entity might make a good takeover target, I am wondering how easily that might be achieved with Toyota having 15% ownership.

Who loses potential supply that they were eyeing off as a result of this merger?
If a takeover is going to take place, I am wondering if now is the time to do it?
With Galaxy's profitability increasing substantially more than that of Orocobre how could an Independent Expert say that this is a good deal for Galaxy shareholders?

Also, we could see that Galaxy's share price yesterday morning didn't match the merger attributed value.... Galaxy was well ahead....

I would also put to everyone that by Galaxy not presenting to the market a plan for a converter tied to James Bay at the time of that announcement that it affected the share price negatively, and I would use Piedmont as an example of what might have occurred had they bothered to do so. - This would have probably improved Galaxy's shareholders value going into the new entity.

I also wonder how pleased Simon Hay really was with this deal, because if you listen to his answers to the questions I provided, it appeared to me that he was not and was just going through the motions he was told to do.

It's also worth noting that members of Galaxy receive bonuses as a result of this deal, they are not diluted and disadvantaged in any way.

It's such a poor deal that I don't think it would be difficult for another party to come along and scuttle the plan.

Expand

"It's such a poor deal that I don't think it would be difficult for another party to come along and scuttle the plan."

Oh really? Without any due diligence?

GXY Price at posting: $3.68 Sentiment: Buy Disclosure: Not Held
8 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

There are more pages in this discussion • 375 more messages in this thread...

First 320 Last

Add GXY (ASX) to my watchlist

Ann: Orocobre and Galaxy Merger - Announcement, page-320

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

BCI reaches close of funding facility for salt-first part of Mardie project

Featured News